CA
NZ
UK
AU
IND
US
GeoVax Labs (NASDAQ:GOVX) is a clinical-stage biotech wagering that the world's renewed appetite for pandemic preparedness will finally reward its vaccine and immuno-oncology pipeline. In 2026 that story has grown louder: a public-health emergency, a bullish analyst target, and a fresh capital raise have …
Kairos Pharma (NYSE American:KAPA) is a clinical-stage oncology minnow chasing an outsized idea: reversing the drug resistance that eventually defeats most cancer therapies. At last closing, the Los Angeles company said it had struck a collaboration with pharmaceutical giant Bayer to test its lead …
CNS Pharmaceuticals (NASDAQ:CNSP) has spent 2026 tearing down and rebuilding itself. The Houston-based clinical-stage biotech, once defined almost entirely by its glioblastoma drug Berubicin, installed a new chief executive in January, unveiled a sweeping strategic pivot in March, and then closed an oversubscribed $22.5 …
EnVVeno Medical (NASDAQ:NVNO) is a clinical-stage medical device company chasing a large, underserved market: severe deep chronic venous insufficiency, a debilitating condition affecting an estimated three million Americans. At last closing, the company was granted its first U.S. patent covering the enVVe System, its …
HeartSciences (NASDAQ:HSCS) is attempting one of the more dramatic corporate reinventions on the small-cap market. The cardiac-diagnostics company has agreed to an all-stock business combination with Fortitude Mining Holdings, a Zcash mining platform owned by Digital Currency Group. If shareholders approve, HSCS would effectively …
Shares of Nexalin Technology (NASDAQ:NXL) tell two stories at once. The Houston-based neurostimulation company has strung together headline-grabbing milestones in 2026 - a pivotal insomnia trial, a digital-health acquisition and a rare mention in a federal appropriations bill. Yet the stock changes hands well …
SenesTech (NASDAQ:SNES) sells something unusual in the pest-control aisle: birth control for rats. The Phoenix-based micro-cap makes fertility-limiting soft baits designed to shrink rodent populations without poison. In May 2026 the company installed Michael Edell as president and chief executive, a commercially minded operator …
Acurx Pharmaceuticals (NASDAQ:ACXP) is a late-stage antibiotic developer with an unusually pointed pitch: a single drug that could both treat acute Clostridioides difficile infection (CDI) and stop it from coming back. That drug, ibezapolstat, leans on a microbiome-sparing mechanism the company argues sets it …
Autonomix Medical (NASDAQ:AMIX) is a clinical-stage medical-technology company chasing an ambitious goal: reading and treating the nervous system from inside blood vessels. In May 2026 it was granted a U.S. patent covering transvascular monitoring and treatment with real-time procedural feedback, reinforcing the intellectual property …
Dermata Therapeutics (NASDAQ:DRMA) is a rare sight in biotech: a company that hit its primary endpoint in a pivotal trial and then chose not to pursue drug approval. After its lead acne candidate, Xyngari (formerly DMT310), met statistical significance in the Phase 3 STAR-1 …
Please wait processing your request...